The timeline of nanobody development reflects a steady series of innovations. In 2001, the term "nanobody" was introduced by ...

The FDA has approved Emrelis to treat adults with locally advanced or metastatic NSCLC with high c-Met protein overexpression.

The agency granted accelerated approval based on a 35 percent response rate and more than 14 months of median overall survival in high expressers.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 ...

BI 771716 (NCT06722157) is a highly specific antibody fragment designed to optimize penetration through the retinal layers to target the GA pathology. BI 771716 was developed by Boehringer Ingelheim ...

Researchers used AI models to design antibodies that neutralize over 1,300 SARS-CoV-2 strains, including Delta and Omicron.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) ...

Six months after entering talks with U.S. private equity firm Clayton, Dubilier & Rice (CD&R), Sanofi has closed ... Bio’s clinical-stage bispecific antibody, DR-0201. Sanofi paid $600 million ...

Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi retains a significant shareholding of Opella with a 48.2% stake.